Category

Photos

The latest published reporting in this category.

Crypto

Anthropic Targets Over $1 Trillion Valuation in Upcoming IPO Amid AI Market Volatility

Anthropic has announced plans for a $64.4 billion IPO, targeting a valuation of up to $1.4 trillion despite growing investor concerns over AI infrastructure spending and recent stock market volatility. Ad Ad Anthropic IPO Targets Valuation Above $1.4 Trillion According to the report, Anthropic plans to sell 825 million shares at prices ranging from $70 The post Anthropic Targets Over $1 Trillion Valuation in Upcoming IPO Amid AI Market Volatility appeared first on CoinGape.

CoinGape
Read more
Crypto

Anthropic IPO Targets Up to $64.35 Billion in Share Sales

The post Anthropic IPO Targets Up to $64.35 Billion in Share Sales appeared first on Coinpedia Fintech News Anthropic plans to offer 825 million shares at an indicative price of $70–$78 each, targeting up to $64.35 billion through its public offering, according to a draft prospectus reviewed by Reuters. The proposed offering could raise between $57.75 billion and $64.35 billion. The company is also planning a $26 billion private placement involving major technology …

Coinpedia
Read more
Crypto

These two Wall Street veterans are raising funds to build a hedge fund, and they want to directly let AI manage it

Wall Street veterans Alex Popa and Charles Elkan are working on a stock hedge fund that is mainly operated by artificial intelligence agents and models […] These two Wall Street veterans are raising funds to build a hedge fund, and they want to directly let AI do the trading> This article was first published in BlockTempo "Dongzone Trend - the most influential blockchain news media".

動區動趨 BlockTempo
Read more
Finance

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by companies on weight loss, according to a report from the Netherlands-based non-profit group. Continue readin

The Guardian
Read more